SCHEMBL3527170

SCHEMBL3527170

CCn1c(C2CC2)c(C2CC2)c(=O)n1-c1ccccc1C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 4/20 0.46
CYP3A4 P08684 2/20 0.46
P2RX7 Q99572 4/20 0.36
L3MBTL1 Q9Y468 6/20 0.35
ALDH1A1 P00352 1/20 0.35
KMT2A Q03164 1/20 0.34
TDP1 Q9NUW8 2/20 0.34
POLB P06746 1/20 0.34
HCAR1 Q9BXC0 2/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3526545 0.88 CYP3A4 (0.41) HSD11B1CYP3A4P2RX7L3MBTL1ALDH1A1
SCHEMBL3530125 0.87 CYP3A4 (0.43) HSD11B1CYP3A4P2RX7L3MBTL1KMT2A
SCHEMBL3526762 0.86 HSD11B1 (0.43) HSD11B1CYP3A4P2RX7L3MBTL1ALDH1A1
SCHEMBL3527102 0.84 HSD11B1 (0.57) HSD11B1CYP3A4L3MBTL1ALDH1A1KMT2A
SCHEMBL3528034 0.82 HSD11B1 (0.42) HSD11B1P2RX7HCAR1KDM4E
SCHEMBL3526821 0.81 HSD11B1 (0.54) HSD11B1CYP3A4L3MBTL1ALDH1A1KMT2A
SCHEMBL3527054 0.78 HSD11B1 (0.59) HSD11B1CYP3A4L3MBTL1ALDH1A1KMT2A
SCHEMBL3535897 0.77 HSD11B1 (0.39) HSD11B1CYP3A4P2RX7L3MBTL1KMT2A
SCHEMBL3526443 0.75 HSD11B1 (0.53) HSD11B1CYP3A4L3MBTL1ALDH1A1TDP1
SCHEMBL3528722 0.75 HSD11B1 (0.56) HSD11B1CYP3A4L3MBTL1ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652057-B2 Pyrazolones as 11b-HSD1 inhibitors for diabetes HOFFMAN-LA ROCHE INC. (US) 2010-01-26 US claimed
EP-1924562-A2 PYRAZOLONE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-05-28 EP claimed
WO-2007025880-A2 PYRAZOLONE DERIVATIVES AS 11-BETA HSD1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-03-08 WO claimed
US-20070049574-A1 New pyrazolones as 11b-HSD1 inhibitors for diabetes F. HOFFMANN-LA ROCHE AG (CH) 2007-03-01 US claimed
US-7652057-B2 Pyrazolones as 11b-HSD1 inhibitors for diabetes HOFFMAN-LA ROCHE INC. (US) 2010-01-26 US disclosed
EP-1924562-A2 PYRAZOLONE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-05-28 EP disclosed
WO-2007025880-A2 PYRAZOLONE DERIVATIVES AS 11-BETA HSD1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-03-08 WO disclosed
US-20070049574-A1 New pyrazolones as 11b-HSD1 inhibitors for diabetes F. HOFFMANN-LA ROCHE AG (CH) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049574-A1 New pyrazolones as 11b-HSD1 inhibitors for diabetes HSD11B1, HSD17B1, HSD17B7 HSD11B1 1/4885CYP3A4 45/4885P2RX7 2161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.